Novartis To Launch Galvus In EU With Lower Dosing Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
EU approves DPP-4 inhibitor with label recommending 50 mg once or twice daily depending on type of combination therapy prescribed.
You may also be interested in...
Novartis To Launch Galvus/Metformin Combo Pill In Europe
Combination vildagliptin and metformin therapy will be available in the next few weeks, firm says.
Novartis To Launch Galvus/Metformin Combo Pill In Europe
Combination vildagliptin and metformin therapy will be available in the next few weeks, firm says.
Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.